Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis

Pengcheng Luo, Hsin Hsin Chang, Yiqiang Zhou, Shali Zhang, Sung Hee Hwang, Christophe Morisseau, Cong Yi Wang, Edward W. Inscho, Bruce D. Hammock, Mong Heng Wang

Research output: Contribution to journalArticle

84 Scopus citations

Abstract

Soluble epoxide hydrolase (sEH) is an enzyme involved in the metabolism of endogenous inflammatory and antiapoptotic mediators. However, the roles of sEH in diabetes and the pancreas are unknown. Our aims were to determine whether sEH is involved in the regulation of hyperglycemia in diabetic mice and to investigate the reasons for the regulation of insulin secretion by sEH deletion or inhibition in islets. We used two separate approaches, targeted disruption of Ephx2 gene [sEH knockout (KO)] and a selective inhibitor of sEH [trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB)], to assess the role of sEH in glucose and insulin homeostasis in streptozotocin (STZ) mice. We also examined the effects of sEH KO or t-AUCB on glucose-stimulated insulin secretion (GSIS) and intracellular calcium levels in islets. Hyperglycemia in STZ mice was prevented by both sEH KO and t-AUCB. In addition, STZ mice with sEH KO had improved glucose tolerance. More important, when insulin levels were assessed by hyperglycemic clamp study, sEH KO was found to promote insulin secretion. In addition, sEH KO and t-AUCB treatment augmented islet GSIS. Islets with sEH KO had a greater intracellular calcium influx when challenged with high glucose or KCl in the presence of diazoxide. Moreover, sEH KO reduced islet cell apoptosis in STZ mice. These results show not only that sEH KO and its inhibition prevent hyperglycemia in diabetes, but also that sEH KO enhances islet GSIS through the amplifying pathway and decreases islet cell apoptosis in diabetes.

Original languageEnglish (US)
Pages (from-to)430-438
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume334
Issue number2
DOIs
StatePublished - Aug 2010

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Luo, P., Chang, H. H., Zhou, Y., Zhang, S., Hwang, S. H., Morisseau, C., Wang, C. Y., Inscho, E. W., Hammock, B. D., & Wang, M. H. (2010). Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. Journal of Pharmacology and Experimental Therapeutics, 334(2), 430-438. https://doi.org/10.1124/jpet.110.167544